AR078786A1 - Derivados de la cromenona - Google Patents
Derivados de la cromenonaInfo
- Publication number
- AR078786A1 AR078786A1 ARP100103937A AR078786A1 AR 078786 A1 AR078786 A1 AR 078786A1 AR P100103937 A ARP100103937 A AR P100103937A AR 078786 A1 AR078786 A1 AR 078786A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halogen
- independently selected
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
Composiciones farmacéuticas que los contienen y sus usos en la elaboracion de un medicamento para utilizar en el tratamiento de trastornos de proliferacion celular. Reivindicacion 1: Un compuesto de formula (1) caracterizado porque: R1 es H o alquilo C1-4 sustituido opcionalmente por 1, 2 o 3 sustituyentes seleccionados independientemente de halogeno, hidroxi o alcoxi C1-3; R2 es alquilo C1-4 o alcoxi C1-4, cualquiera de los cuales puede estar opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados independientemente de halogeno, hidroxi, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3, ciano, alquil C1-3amino o di[alquil C1-3]amino; o R1 y R2 juntos forman un nitrogeno de 3 a 8 miembros que contiene un sistema de anillo heterociclilo, que contiene opcionalmente 1 o 2 heteroátomos más seleccionados de oxígeno, nitrogeno y azufre, donde un átomo de azufre del anillo se oxida opcionalmente para formar el/los S-oxido(s), y dicho anillo puede estar opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados independientemente de halogeno, hidroxi, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3, oxo, hidroxialquilo C1-3, halogeno-alquilo C1-3 y alcoxi C1-3-alquilo C1-3; R3 es H o alquilo C1-3; R4 y R5 se seleccionan independientemente de H, halogeno, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3 y ciano; o R4 y R5 juntos forman un anillo fenilo o un anillo heterociclilo de 5 o 6 miembros o un anillo heteroarilo de 5 o 6 miembros, donde el anillo heterociclilo o anillo heteroarilo contiene 1, 2 o 3 heteroátomos seleccionados de oxígeno y nitrogeno, y dicho anillo fenilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados independientemente de halogeno, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3 y ciano; R6, R7 y R8 se seleccionan independientemente de H, halogeno, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3 y ciano; n es 0, 1, 2, 3 o 4; cada grupo R9 es alquilo C1-3; o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306017 | 2009-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078786A1 true AR078786A1 (es) | 2011-11-30 |
Family
ID=43085922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103937 AR078786A1 (es) | 2009-10-27 | 2010-10-26 | Derivados de la cromenona |
Country Status (41)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| UY34013A (es) * | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| MX361136B (es) | 2013-01-23 | 2018-11-28 | Astrazeneca Ab | Compuestos quimicos. |
| CN105142629B (zh) * | 2013-03-04 | 2018-11-23 | 阿斯利康(瑞典)有限公司 | 组合治疗 |
| SG11201609527PA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
| CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| CA2952037A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| MX2016016528A (es) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa. |
| CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| KR102630111B1 (ko) * | 2015-10-09 | 2024-01-25 | 얀센 파마슈티카 엔브이 | PI3Kβ 저해제로서의 퀴녹살린 및 피리도피라진 유도체 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20210141214A (ko) * | 2020-05-15 | 2021-11-23 | 제이투에이치바이오텍 (주) | 3원환 화합물 및 이의 의약 용도 |
| CN117615763A (zh) * | 2021-02-01 | 2024-02-27 | 健道生物医药有限公司 | 磷酸肌醇3激酶β抑制剂及其组合物和制备方法 |
| KR20240004744A (ko) * | 2021-05-03 | 2024-01-11 | 페트라 파마 코포레이션 | 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 |
| EP4333984A1 (en) | 2021-05-03 | 2024-03-13 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| WO2022251482A1 (en) * | 2021-05-27 | 2022-12-01 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| WO2024081904A1 (en) * | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | Methods for treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6027A (en) * | 1849-01-09 | Rotary blacksmith s twyer | ||
| JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類 |
| CA2081577A1 (en) | 1990-06-20 | 1991-12-21 | Ronald B. Gammill | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1, 3-benzoxazine-4-ones |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
| EP1857443B1 (en) | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| CA2495661C (en) * | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| SI2004654T1 (sl) * | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2112145A1 (en) | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
| WO2010134082A1 (en) | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2010
- 2010-10-22 US US12/909,968 patent/US8399460B2/en active Active
- 2010-10-25 RS RS20150090A patent/RS53813B1/en unknown
- 2010-10-25 EP EP10769052.1A patent/EP2493870B1/en active Active
- 2010-10-25 KR KR1020127012933A patent/KR101738195B1/ko active IP Right Grant
- 2010-10-25 MX MX2012005027A patent/MX2012005027A/es active IP Right Grant
- 2010-10-25 PT PT10769052T patent/PT2493870E/pt unknown
- 2010-10-25 EA EA201200618A patent/EA020523B9/ru not_active IP Right Cessation
- 2010-10-25 CA CA2776994A patent/CA2776994C/en active Active
- 2010-10-25 AU AU2010311107A patent/AU2010311107B9/en active Active
- 2010-10-25 MY MYPI2012001831A patent/MY179833A/en unknown
- 2010-10-25 JP JP2012535931A patent/JP5657010B2/ja active Active
- 2010-10-25 NZ NZ599457A patent/NZ599457A/en not_active IP Right Cessation
- 2010-10-25 DK DK10769052.1T patent/DK2493870T3/en active
- 2010-10-25 ME MEP-2015-21A patent/ME02050B/me unknown
- 2010-10-25 SI SI201030875T patent/SI2493870T1/sl unknown
- 2010-10-25 CN CN201080060262.7A patent/CN102712615B/zh active Active
- 2010-10-25 CN CN201410654983.0A patent/CN104447657B/zh active Active
- 2010-10-25 PL PL10769052T patent/PL2493870T3/pl unknown
- 2010-10-25 IN IN3328DEN2012 patent/IN2012DN03328A/en unknown
- 2010-10-25 WO PCT/GB2010/051788 patent/WO2011051704A1/en active Application Filing
- 2010-10-25 ES ES10769052T patent/ES2530943T3/es active Active
- 2010-10-25 UA UAA201206000A patent/UA107474C2/uk unknown
- 2010-10-25 PE PE2012000578A patent/PE20130149A1/es active IP Right Grant
- 2010-10-25 BR BR112012010124A patent/BR112012010124B8/pt active IP Right Grant
- 2010-10-26 AR ARP100103937 patent/AR078786A1/es active IP Right Grant
- 2010-10-27 SA SA110310808A patent/SA110310808B1/ar unknown
- 2010-10-27 UY UY32978A patent/UY32978A/es not_active Application Discontinuation
- 2010-10-27 TW TW099136762A patent/TWI483939B/zh active
-
2012
- 2012-04-15 IL IL219191A patent/IL219191A0/en not_active IP Right Cessation
- 2012-04-25 CL CL2012001056A patent/CL2012001056A1/es unknown
- 2012-04-26 CO CO12068977A patent/CO6541528A2/es active IP Right Grant
- 2012-04-27 GT GT201200126A patent/GT201200126A/es unknown
- 2012-04-27 CR CR20120217A patent/CR20120217A/es unknown
- 2012-04-27 DO DO2012000124A patent/DOP2012000124A/es unknown
- 2012-04-27 EC ECSP12011838 patent/ECSP12011838A/es unknown
- 2012-04-27 CU CU2012000069A patent/CU20120069A7/es unknown
- 2012-04-27 HN HN2012000889A patent/HN2012000889A/es unknown
- 2012-04-27 NI NI201200081A patent/NI201200081A/es unknown
-
2013
- 2013-01-22 HK HK13100967.4A patent/HK1174027A1/xx unknown
- 2013-02-13 US US13/765,850 patent/US8673906B2/en active Active
-
2014
- 2014-01-24 US US14/163,105 patent/US9029374B2/en active Active
- 2014-11-20 JP JP2014235289A patent/JP5872016B2/ja active Active
-
2015
- 2015-02-05 HR HRP20150146TT patent/HRP20150146T1/hr unknown
- 2015-02-12 SM SM201500036T patent/SMT201500036B/xx unknown
- 2015-02-13 CY CY20151100157T patent/CY1116143T1/el unknown
- 2015-04-08 US US14/681,244 patent/US20160060240A1/en not_active Abandoned
- 2015-07-20 HK HK15106851.8A patent/HK1206335A1/zh unknown
-
2016
- 2016-03-24 US US15/079,633 patent/US9718800B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078786A1 (es) | Derivados de la cromenona | |
| UY28578A1 (es) | Derivados de amida | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| UY29301A1 (es) | Derivados amida | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| AR045529A1 (es) | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
| AR063147A1 (es) | Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central. | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| ECSP088257A (es) | Derivados de amida | |
| AR055344A1 (es) | Derivados de 1-oxoindano y 1-oxo-2,3-dihidroisoindol como inhibidores de p38, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la cinasa p38 | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |